PYTX-002 / Papyrus Therap, Oxford BioTherapeutics - LARVOL DELTA

Papyrus Therapeutics Inc. Signs Research Collaboration With Oxford Biomedica (Businesswire) - "Papyrus Therapeutics, Inc...and Oxford Biomedica plc...announced today the signing of a research collaboration agreement...The collaboration includes the assessment of the impact and therapeutic benefit of Papyrus’ PYTX-002, a potential first-in-class gene replacement therapy that will confer ‘cellular pharmacy’ properties on a CAR-T cell therapy developed by Oxford Biomedica, initially in preclinical in vivo models of solid tumors."

Licensing / partnership • Oncology • Solid Tumor